Eloxx Pharmaceuticals (NASDAQ:ELOX) Now Covered by Analysts at Lifesci Capital

Stock analysts at Lifesci Capital initiated coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a research note issued to investors on Wednesday,Benzinga reports. The firm set an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital’s price objective suggests a potential upside of 239.27% from the stock’s previous close.

Separately, Guggenheim initiated coverage on shares of Eloxx Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $43.00 price target on the stock. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $41.50.

Eloxx Pharmaceuticals Price Performance

ELOX stock traded down $0.21 during mid-day trading on Wednesday, hitting $11.79. 237,015 shares of the company were exchanged, compared to its average volume of 25,218. The firm has a market cap of $8.14 million, a P/E ratio of -0.77 and a beta of -1,891.27. Eloxx Pharmaceuticals has a twelve month low of $11.42 and a twelve month high of $17.50. The stock’s fifty day moving average is $17.32.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.